Our mission is to find and enable convenient, affordable, and accessible solutions to stop AMD in its early stages, before it causes sight loss.
AMD destroys central vision leaving a person unable to read, drive, or recognise faces. It is associated with social isolation, loneliness, falls, poorer general health and significant impact on mental health including depression.
To date, only patients with the wet form of AMD (10% of people diagnosed with AMD) can be treated with regular injections of a drug into the eyeball.
There are no treatments for the remaining patients with the dry form of AMD, nor there are any approved medicines to stop early AMD from progressing into its late stages.
In order to address the anticipated increase in AMD incidence due to a globally ageing population, we have to act now. And the solution needs to be comprehensive and inclusive of all: safe, cheap and accessible - so no patients are left behind.